A practical reference on BDNF: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-06-16. Anything still debated is marked as such rather than presented as settled.
Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.
Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.
Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.
Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.
Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.
| Property | Value | Notes |
|---|---|---|
| Principal proposed target | GABA-A receptor complex | Hypothesis derived mainly from animal pharmacology |
| Common behavioral assay | Elevated plus maze | Rodent test for anxiety-like behavior |
| Reported molecular marker | Hippocampal BDNF expression | Measured by immunoassay or mRNA quantification |
| Typical dosing route | Intranasal | Chosen to reduce first-pass metabolism |
| Reported plasma half-life | Minutes | Based on limited peptide stability data |
Tuftsin, the parent structure, is a naturally occurring immunomodulatory tetrapeptide released from the Fc region of immunoglobulin G by spleen enzymes. Selank extends this four-residue sequence with three additional amino acids. The stated rationale is that the added tail slows enzymatic breakdown and may influence receptor interactions. How the full heptapeptide behaves at the molecular level is not firmly established, and proposed mechanisms often involve indirect modulation of neurotransmitter or immune signaling rather than a single defined target.
Selank is a synthetic heptapeptide developed in Russia. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, a seven-residue chain built around the natural tetrapeptide tuftsin. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences first described the compound in the mid-1990s. The design combined the tuftsin core with an added Pro-Gly-Pro tail, a modification intended to extend the molecule's stability in biological fluids. Published work on the peptide has appeared mainly in Russian-language journals.
Reported activity for Selank centers on anxiolytic and nootropic effects. Russian clinical reports describe use in anxiety and in cognitive or attention-related complaints. Most of this evidence comes from studies conducted by the same research groups that developed the peptide. Independent replication in other countries remains limited, and no major Western regulatory agency has approved the compound for any indication. The gap between local reports and external verification is a recurring point in discussions of the peptide.
Regulatory treatment varies by jurisdiction. In Russia the compound is a registered prescription product, while in the European Union and the United States it is generally handled as a research chemical without a marketing authorization. Suppliers therefore operate outside pharmaceutical oversight, and buyers rely on supplier documentation for purity and identity claims. Chain of custody and third-party testing are the main verification tools. Analysts note that the absence of a pharmacopoeial monograph for research-grade material limits standardization across vendors.
Purity assessment relies mainly on reverse-phase high-performance liquid chromatography with ultraviolet detection. Because the peptide lacks a strong chromophore, detection often uses backbone absorbance near 214 nm. Identity is confirmed by mass spectrometry, typically electrospray ionization or matrix-assisted laser desorption, comparing the measured mass against the expected value. Amino acid analysis can verify composition after acid hydrolysis. Diastereomer content and residual counterions are reported less often, although both can influence biological assays.
Most published work on selank originates from a small number of research groups in the Russian Federation. A large share of that record appears in Russian-language journals, which limits access for readers who rely on English-indexed databases. Independent replication by laboratories outside the original research network is sparse in publicly available sources. This concentration of origin and language is a frequently noted feature when the compound is summarized in broader reviews of synthetic peptides.
Reported pharmacological effects center on reduced anxiety-like behavior in animal models and on measures of memory and learning. Proposed contributing mechanisms include modulation of GABAergic signaling, shifts in monoamine turnover, and changes in the activity of enzymes that degrade neuropeptides. Effects on the expression of genes linked to neuroplasticity have also been described. No single molecular target is widely accepted, and whether the behavioral findings arise from one pathway or several remains an open question.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed as a stabilized analogue of tuftsin, a naturally occurring tetrapeptide fragment derived from the immunoglobulin heavy chain. The additional Pro-Gly-Pro segment at the carboxyl terminus is intended to slow enzymatic cleavage. The compound is usually described in the literature as a synthetic peptide with anxiolytic and cognitive-related activity, a label that reflects a research context rather than an approved therapeutic category.
== History == The discovery of nanocellulosic materials can be traced back to late 1940s studies on the hydrolysis of cellulose fibers. Eventually it was noticed that cellulose hydrolysis seemed to occur preferentially at some disordered intercrystalline portions of the fibers. This led to the obtention of colloidally stable and highly crystalline nanorods particles. These particles were first referred to as micelles, before being given multiple names including cellulose nanocrystals (CNCs), nanocrystalline cellulose (NCC), or cellulose (nano)whiskers, though this last term is less used today. Later studies by O. A. Battista showed that in milder hydrolysis conditions, the crystalline nanorods stay aggregated as micron size objects. This material was later referred to as microcrystalline cellulose (MCC) and commercialised under the name Avicel by FMC Corporation.
Сорокин) "Rugby" (Регби) in English translation of Great Soviet Encyclopedia (Progress Publishers, Moscow, 1978) Starmer-Smith, Nigel (ed) Rugby - A Way of Life, An Illustrated History of Rugby (Lennard Books, 1986 ISBN 0-7126-2662-X) Thau, Chris Soviet Rugby in Starmer-Smith, Nigel & Robertson, Ian (eds) The Whitbread Rugby World '89 (Lennard Books, 1988 ISBN 1-85291-038-0) Thau, Chris Soviet Students in Starmer-Smith, Nigel & Robertson, Ian (eds) The Whitbread Rugby World '90 (Lennard Books, 1989 ISBN ) The Ultimate Encyclopaedia of Rugby, (Carlton Books, 1997 ISBN 1-85868-076-X) Dancing On Our Bones: New Zealand, South Africa, Rugby and Racism by Trevor Richards (Bridget Williams Books, 1999). The author was one of a small group of people who founded Halt All Racist Tours (HART) in Auckland in 1969 and worked for the organisation for many years, serving as chair (1969–1980) and international secretary (1980–1985).
sex linkage The presence of a particular gene or DNA sequence on a sex chromosome (in mammals either the X chromosome or the Y chromosome) rather than on an autosome; these genes are said to be sex-linked. Expression of sex-linked genes varies by organism depending on the mechanism of sex determination and the types of sex chromosomes present, but the associated phenotypes often exclusively appear in either the homogametic or heterogametic sex.
== Types == The structure of the nanotube is not changed if the strip is rotated by 60 degrees clockwise around A1 before applying the hypothetical reconstruction above. Such a rotation changes the corresponding pair (n,m) to the pair (−m,n+m). It follows that many possible positions of A2 relative to A1 — that is, many pairs (n,m) — correspond to the same arrangement of atoms on the nanotube. That is the case, for example, of the six pairs (1,2), (−2,3), (−3,1), (−1,−2), (2,−3), and (3,−1). In particular, the pairs (k,0) and (0,k) describe the same nanotube geometry. These redundancies can be avoided by considering only pairs (n,m) such that n > 0 and m ≥ 0; that is, where the direction of the vector w lies between those of u (inclusive) and v (exclusive). It can be verified that every nanotube has exactly one pair (n,m) that satisfies those conditions, which is called the tube's type. Conversely, for every type there is a hypothetical nanotube. In fact, two nanotubes have the same type if and only if one can be conceptually rotated and translated so as to match the other exactly. Instead of the type (n,m), the structure of a carbon nanotube can be specified by giving the length of the vector w (that is, the circumference of the nanotube), and the angle α between the directions of u and w may range from 0 (inclusive) to 60 degrees clockwise (exclusive). If the diagram is drawn with u horizontal, the latter is the tilt of the strip away from the vertical.
Sources: en.wikipedia.org
to improve the resolution of analytes that co-elute with the micellar phase. These agents, however, may alter the level of the EOF. Cyclodextrins are cyclic polysaccharides that form inclusion complexes that can cause competitive hydrophobic partitioning of the analyte. Since analyte-cyclodextrin complexes are neutral, they will migrate toward the cathode at a higher velocity than that of the negatively charged micelles. Mixed micelle systems, such as the one formed by combining SDS with the non-ionic surfactant Brij-35, can also be used to alter the selectivity of MEKC.
=== Inflammation === Neuroinflammation is considered a contributing mechanism in Parkinson's disease. Research has shown lasting activation of the brain's immune cells, microglia, in regions affected by the disease, suggesting that inflammation may play a role in the gradual loss of dopamine-producing neurons. While immune responses can be protective in the short term, chronic inflammation may damage neurons over time. Dopaminergic neurons appear to be particularly vulnerable under inflammatory conditions. The normal production and breakdown of dopamine already place these cells under higher stress than other neurons. When inflammation is present, this may increase the neurons' susceptibility to damage and speed up degeneration. Changes in dopamine signaling may then influence immune activity in the brain, creating a feedback loop to further worsen neuronal loss.
=== By Administration === Medicines can also be categorized based on how they are administered. The route of administration can affect the speed and effectiveness of treatment. Below is a summary of common routes:
The BioBricks assembly standard was described and introduced by Tom Knight in 2003 and it has been constantly updated since then. Currently, the most commonly used BioBricks standard is the assembly standard 10, or BBF RFC 10. BioBricks defines the prefix and suffix sequences required for a DNA part to be compatible with the BioBricks assembly method, allowing the joining of all DNA parts which are in the BioBricks format. The prefix contains the restriction sites for EcoRI, NotI and XBaI, while the suffix contains the SpeI, NotI and PstI restriction sites. Outside of the prefix and suffix regions, the DNA part must not contain these restriction sites. To join two BioBrick parts together, one of the plasmids is digested with EcoRI and SpeI while the second plasmid is digested with EcoRI and XbaI. The two EcoRI overhangs are complementary and will thus anneal together, while SpeI and XbaI also produce complementary overhangs which can also be ligated together. As the resulting plasmid contains the original prefix and suffix sequences, it can be used to join with more BioBricks parts. Because of this property, the BioBricks assembly standard is said to be idempotent in nature. However, there will also be a "scar" sequence (either TACTAG or TACTAGAG) formed between the two fused BioBricks.
=== Pregnancy-associated malaria (Placental malaria) === A study on Ghanaian population showed that MMP-9 single nucleotide polymorphism 1562 C > T (rs3918242) was protective against placental malaria which suggests a possible role of MMP-9 in susceptibility to malaria.
Sources: en.wikipedia.org
Intranasal administration predominates in both animal and human research because it avoids hepatic first-pass metabolism. Injectable and intraperitoneal routes appear in animal work mainly for comparison.
Behavioral endpoints include time spent in open arms of the elevated plus maze and avoidance latencies. Biochemical endpoints include BDNF concentration, cytokine levels, and monoamine metabolite ratios in brain tissue.
Most published studies are small, originate from a limited number of laboratories, and lack independent replication. Dose-response relationships, measured brain exposure, and long-term outcomes are not well characterized.
Reports describe modulation of GABA signalling, changes in monoamine turnover and effects on neurotrophic factor expression. These observations come mainly from animal and cell studies. A single unifying mechanism has not been demonstrated.